S&P/ASX 200 Index (ASX: XJO) shares are 0.14% higher at 8,828.7 points on Tuesday. 

The fastest rising ASX 200 share today is WiseTech Global Ltd (ASX: WTC), which has recovered 4% after yesterday’s smashing.

ASX 200 healthcare shares Telix Pharmaceuticals Ltd (ASX: TLX) and Mesoblast Ltd (ASX: MSB) are also among the top risers today.

Both stocks are up by more than 3.5%.

Meanwhile, let’s check out 3 ASX 200 shares with new ratings from the experts (courtesy The Bull).

Charter Hall Group (ASX: CHC)

The Charter Hall share price is $22.73, down 0.5% today and down 7% in the calendar year to date (YTD). 

Toby Grimm from Baker Young has a buy rating on this real estate investment trust (REIT).

The analyst said: 

Australia’s leading diversified property group has benefited from a strong funds management performance driving multiple earnings upgrades in the past financial year.

With the strong operational trend continuing amid a potential respite in interest rates, the stock offers compelling exposure in a lagging sector that may be a beneficiary of a swing against banks.

The shares have been enjoying favourable momentum since May 20, increasing from $18.80 to trade at $23.15 on June 18.

Cochlear Ltd (ASX: COH)

The Cochlear share price is $112.38, down 0.5% today and down 57% YTD.

Christopher Watt from Bell Potter has a hold rating on this ASX 200 healthcare share. 

Watt explained: 

The long term opportunity for this hearing implants maker remains compelling, supported by a large addressable market, strong brand position and an attractive product pipeline.

However, near term trading conditions have softened in response to weaker referral activity in the US, hospital capacity constraints in Europe and reimbursement changes in China.

Until there’s clearer evidence that volumes are stabilising, a more balanced stance is appropriate.

The long term growth story and product pipeline remain intact.

The S&P/ASX 200 Health Care Index (ASX: XHJ) fell to a 9-year low on 3 June due to many industry headwinds over the past year.

Since then, ASX 200 healthcare shares have been on a comeback, rising 11.5% compared to a 0.4% bump for the broader ASX 200.

Northern Star Resources Ltd (ASX: NST)

The Northern Resources share price is $20.93, down 1.3% on Tuesday and down 14% YTD. 

Grimm has a sell rating on this ASX 200 gold mining share.

He explained:

The emergence of prominent US based activist investor Elliott Investment Management has prompted optimism surrounding the gold miner.

However, in our view, it doesn’t alter the underperformance of NST’s asset base involving production volumes, costs and capital expenditure requirements.

A new management team will likely rebase expectations. But we would seek alternative gold exposure for those still playing the theme.

The shares have fallen from $31.73 on March 2 to trade at $21.44 on June 18.

Elliot Investment recently disclosed it has a 3% to 4% stake in Northern Star shares.

It also suggested ways that Northern Star management could improve returns for shareholders.

You can read Northern Star’s response here.

The post Buy, hold, sell: Charter Hall, Northern Star, Cochlear shares appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Tuesday
• With the gold price up on Monday, are Northern Star shares a good buy now?
• 3 ASX healthcare shares to sell despite signs of sector rebound
• Why CSL, Westpac, and this big-name ASX 200 share could be sells
• Experts name 3 ASX 200 shares to buy

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Telix Pharmaceuticals. The Motley Fool Australia has recommended Cochlear and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares are enjoying a welcome day of outperformance today.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech giant closed yesterday trading for $112.88. In morning trade on Tuesday, shares are changing hands for $113.38, up 0.4%.

For some context, the ASX 200 is down 0.1% at this same time.

I mention today’s outperformance as ‘welcome’ because, longer term, the ASX healthcare share has been having a tough time of it.

How tough?

Well, despite today’s uptick, shares remain down a steep 52.9% over the past 12 months. A capital loss that will have only been very modestly eased by the two unfranked dividends the company paid out to eligible stockholders over the last year.

CSL shares trade on a 3.8% unfranked trailing dividend yield.

And if Peak Asset Management’s Niv Dagan has it right, the Aussie biotech company isn’t out of the woods just yet (courtesy of The Bull).

Here’s why.

Time to sell CSL shares?

“A sell rating is justified as this biotechnology giant has materially downgraded its fiscal year 2026 outlook while announcing about $5 billion of additional non-cash pre-tax impairments across fiscal years 2026 and 2027,” Dagan noted.

“Revenue expectations have been reduced due to US immunoglobulin channel normalisation and weaker albumin prices in China,” he added.

Summarising his other potential headwinds facing CSL shares, Dagan concluded:

The CSL Vifor acquisition has under-performed. Also, government healthcare cost pressures and a higher interest rate environment present ongoing challenges for the biotechnology sector, further weighing on sentiment.

What did the ASX 200 healthcare share report?

CSL shares closed down a precipitous 16% on 11 May, the day the company reported on the downgraded FY 2026 outlook Dagan mentioned above.

Investors were overheating their sell buttons after the company cut its FY 2026 revenue guidance to around $15.2 billion, in constant currency. That would represent a 2.5% decline from FY 2025 revenue.

CSL also reduced its full-year net profit after tax and amortisation (NPATA) forecast to approximately $3.1 billion. That’s down 6% from the prior year.

Commenting on the revised forecasts on the day, CSL managing director and CEO Gordon Naylor said, “Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise.”

Naylor added:

As a result, we have now revised down our 2026 financial year guidance.

CSL’s culture and people continue to be first class, the industry is stable and growing, and the company has evident strengths in plasma collections and influenza vaccines. I am confident that the company can be returned to profitable growth and my work is to position the business and the next CEO for success.

The post Down 53%, is it time to throw in the towel on CSL shares? appeared first on The Motley Fool Australia.

More reading

• Should I buy CSL and ResMed shares right now?
• 3 reasons why experts think CSL shares are a sell
• 3 ASX healthcare shares to sell despite signs of sector rebound
• Buy, hold, sell: Life360, Woodside, CSL shares
• Why CSL, Westpac, and this big-name ASX 200 share could be sells

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

WiseTech Global Ltd (ASX: WTC) shares have rebounded strongly in early morning trade on Tuesday.

At the time of writing, WiseTech shares are up over 5% and changing hands for $31.60 a piece.

It’s good news for investors after the stock crashed around 18% to a five-year low on Monday.

It’s been a steep and sustained share price crash for WiseTech shares, driven mostly by a tech-sector-wide sell-off and an investor rotation to more stable assets amid global volatility earlier this year. 

Even after today’s increase, WiseTech shares are still down around 54% for the year to date. They’re also over 70% lower than this time last year.

What happened to WiseTech shares this week?

WiseTech shares fell sharply on Monday after media reports that the Australian Federal Police is investigating founder Richard White over alleged trafficking matters. The matters relate to a former cleaner at WiseTech.

It has been claimed that White exploited a former cleaner’s immigration status and financial position and provided false information on a visa application. 

Investors reacted quickly and rushed to the exits.

Why is the share price climbing higher again today?

In a note to the ASX ahead of the market open this morning, WiseTech has responded to the media reports.

WiseTech said that it notes there was media commentary yesterday alleging an investigation into Richard White, reportedly relating to a visa application. The company said:

The media reports that the alleged investigation relates to Richard White in a personal capacity. There is no suggestion in this media commentary of an investigation into WiseTech.

The Company is not aware of any investigation as outlined in the article. The Executive Chair has provided assurance to the Board that he is not aware of any such investigation and also confirmed that he emphatically and unequivocally denies any involvement in or with human trafficking.

The Company will keep the market updated in accordance with its continuous disclosure obligations.

It looks like the update has helped put investors at ease, and many are buying back into the technology company’s shares this morning.

Should investors buy in the dip or stay clear of WiseTech shares?

The outlook for WiseTech shares is largely unchanged at the time of writing. Brokers and analysts are still very bullish on where we’ll see the share price travel from here.

Market Index shows that the majority of brokers (six out of seven) are very bullish on the ASX tech stock and hold a strong buy rating. The average $72.39 target price implies a potential 130% upside over the next 12 months, at the time of writing.

TradingView data shows something similar. Out of 14 analysts, 11 have a buy or strong buy rating on WiseTech shares. Another three have a hold rating. 

Their average target price is a little lower, at $67.17, but that still implies a potential 113% upside, at the time of writing. The more bullish analysts are tipping an enormous 280% upside to a maximum target price of $119.62.

It looks like it’s time for investors to snap up the shares while they’re at a rock-bottom price.

The post WiseTech shares rebound 5%, responds to media reports: Is it time for investors to buy back in? appeared first on The Motley Fool Australia.

More reading

• WiseTech shares just crashed. Can investors look past the company’s governance issues?
• Why Humm, Metcash, PLS, and WiseTech shares are sinking today
• WiseTech shares crash 12% as founder scandal deepens
• Down but not out: 3 ASX tech shares ripe for a rebound
• Is the only way up for WiseTech shares after a 65% fall?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.